Product Introduction
Bioactivity


英文名: Buflomedil hydrochloride

描述: Buflomedil hydrochloride (Fonzylane) 是一种血管扩张剂，可用于外周动脉疾病引发的一系列症状。

体外活性: Buflomedil可能通过刺激腺苷酸环化酶(BC)或抑制磷酸二酯酶(PTX)提高人类角质形成细胞中的cAMP水平。Buflomedil减少TPA诱导的角质形成细胞中TNF-alpha和IL-8的释放。在微摩尔水平，Buflomedil显著抑制肾上腺素诱导的聚集。Buflomedil对胶原蛋白和ADP诱导的聚集有弱抑制作用。Buflomedil抑制颗粒分泌以及纤维蛋白原与血小板受体的相互作用。Buflomedil抑制组胺相关中性粒细胞的粘附(流动系统)，并在IL-1-4小时后部分抑制粘附(流动和稳定系统)。Buflomedil降低低氧诱导的中性粒细胞粘附以及内皮细胞表面P-选择素的表达。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 7 mg/mL (20.35 mM)
H2O : 63 mg/mL (183.2 mM)
DMSO : 50 mg/mL (145.41 mM)


关键字: Buflomedil | inhibit | Buflomedil hydrochloride | Inhibitor | Buflomedil Hydrochloride

相关产品: Adrenalone hydrochloride | Yohimbine hydrochloride | Betaxolol | Prazosin hydrochloride | Rotigotine- | BMY-14802 hydrochloride | Meranzin hydrate | Paliperidone | Pamatolol | Doxazosin mesylate

相关库: Adrenergic Receptor-Targeted Compound Library | Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Cancer Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compound Library